GLS inhibitors reduce acetyl-CoA and 2-HG level; Compound-968 decreases histone H3K4me3 in breast cancer and Zaprinast reduces H3K9me3 in IDH1-mutant cancer cells. Here, IDH1 is linked to cancer.